Enrique de Ramón Garrido

TL;DR: The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high-dose regimen.

TL;DR: Fewer renal flares were observed in patients receiving MMF but the difference did not reach statistical significance and over a 3-year period, 24 h proteinuria, serum creatinine, serum albumin, serum C3, haemoglobin and global disease activity scores improved similarly in both groups.

TL;DR: Long-term followup of patients from the ELNT confirms that, in lupus nephritis, a remission-inducing regimen of low-dose IV CYC followed by AZA achieves clinical results comparable with those obtained with a high-dose regimen.

TL;DR: HLA-DPB1 locus may contribute to the genetic predisposition to develop antiphospholipid antibodies and clinical manifestations of the APS in patients with SLE.

TL;DR: The importance of the 3'-UTR SNP rs727088 in the regulation of CD226 transcription both in T cells and in NKT cells is supported, supporting an association ofCD226 with SLE in individuals of European ancestry.